Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection

Biomedical Chromatography

Volumn 21, Issue 3, 2007, Pages 310-317

  Yonemoto, Haruo ^a   Ogino, Seiko ^b   Nakashima, Mihoko N ^a   Wada, Mitsuhiro ^a   Nakashima, Kenichiro ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b Sasebo Shiritsu Sogo Hospital   (Japan)

Author keywords

HPLC UV; Paclitaxel; Plasma; Serum

Indexed keywords

BLOOD; EXTRACTION; SIGNAL TO NOISE RATIO;

4-HYDROXYBENZOIC ACIDS; HPLC-UV; HUMAN BLOOD SAMPLES; INTERNAL STANDARDS; LOW DOSE; PACLITAXEL; RAT BLOOD SAMPLES; SERUM; SIMPLE++; UV DETECTION;

RATS;

ACETONITRILE; CARBOPLATIN; CISPLATIN; HEXANE; PACLITAXEL;

ADULT; AGED; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MONITORING; DRUG RETENTION; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIQUID LIQUID EXTRACTION; LOW DRUG DOSE; MALE; NONHUMAN; NORMAL HUMAN; RAT; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; ULTRAVIOLET RADIATION; WISTAR RAT;

RATTUS;

EID: 33947577076     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.759     Document Type: Article

References (29)

1. Alexander MS, Kiser MM, Culley T, Kern JR, Dolan JW, McChesney JD, Zygmunt J and Bannister SJ. Measurement of paclitaxel in biological matrices: high-throughput liquid chromatographic - tandem mass spectrometric quantification of paclitaxel and metabolites in human and dog plasma. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2003; 785: 253-261.
2. Baker AF and Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treatment Reviews 2001; 27: 221-233.
3. Calvert AH. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Seminars in Oncology 1997; 24: S2-85-S2-90.
4. Crowe A. The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with Paclitaxel. European Journal of Pharmacology 2002; 440: 7-16.
5. Donehower RC and Rowinsky EK. An overview of experience with TAXOL (paclitaxel) in the U.S.A. Cancer Treatment Reviews 1993; 19: 63-78.
6. Furue H, Niitani H and Tsukagoshi S. Handbook of Cancer Chemotherapy, 4th Japanese edn. Medical Sciences International: Tokyo, 2001; 3-13.
7. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G and Egorin MJ. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. Journal of Clinical Oncology 1995; 13: 180-190.
8. Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi P and Egorin MJ. Pacitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. Journal of the National Cancer Institute 1995; 87: 1077-1081.
9. He L, Wang GL and Zhang Q. An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. International Journal of Pharmaceutics 2003; 250: 45-50.
10. Huizing MT, Sparreboom A, Rosing H, van Tellingen O, Pinedo HM and Beijnen JH. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. Journal of Chromatography B, Biomedical Applications 1995a; 674: 261-268.
11. Huizing MT, Rosing H, Koopman F, Keung AC, Pinedo HM and Beijnen JH. High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine. Journal of Chromatography B, Biomedical Applications 1995b; 664: 373-382.
12. Lee SH, Yoo SD and Lee KM. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. Journal of Chromatography B, Biomedical Sciences and Applications 1999; 724: 357-363.
13. Noda K, Ikeda M, Kudo R, Nishiya I, Yajima A, Tanaka K, Kodama S, Takahashi T, Tokunaga A, Satoh I, Nozawa S, Taketani Y, Terashima Y, Isonishi S, Takeda Y, Nishijima M, Kuroshima Y, Fujii S, Izumi R, Tamaya T, Mori T, Okada H, Ogita S, Ozaki M and Hatae M. Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1996; 3: 317-325.
14. Parkinson DR, Arbuck SG, Moore T, Pluda JM and Christian MC. Clinical development of anticancer agents from natural products. Stem Cells 1994; 1: 30-43.
15. Robert AP, Ramesh KR, William CZ and Merrill JE. Sensitive liquid chromatography - mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2003; 783: 231-236.
16. Schiff PB and Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proceedings of the National Academy of Sciences of the United States of America 1980; 3: 1561-1565.
17. Sekine I, Nishiwaki Y, Watanabe K, Yoneda S and Saijo N. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clinical Cancer Research 1996; 6: 941-945.
18. Song D and Au JL. Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching. Journal of Chromatography B, Biomedical Applications 1995; 663: 337-344.
19. Sparreboom A, Huizing MT, Boesen JJ, Nooijen WJ, van Tellingen O and Beijnen JH. Isolation, purification, and biological activity of mono- and dihydroxylated Paclitaxel metabolites from human feces. Cancer Chemotherapy and Pharmacology 1995a; 36: 299-304.
20. Sparreboom A, van Tellingen O, Nooijen WJ and Beijnen JH. Determination of Paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. Journal of Chromatography B, Biomedical Applications 1995b; 664: 383-391.
21. Sparreboom A, de Bruijn P, Nooter K, Loos WJ, Stoter G and Verweij J. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B, Biomedical Sciences and Applications 1998; 705: 159-164.
22. Tamura T, Sasaki Y, Eguchi K, Shinkai T, Ohe Y, Nishio M, Kunikane H, Arioka H, Karato A and Omatsu H. Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. Japanese Journal of Cancer Research: Gann 1994; 85: 1057-1062.
23. Tamura T, Sasaki Y, Nishiwaki Y and Saijo N. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Japanese Journal of Cancer Research: Gann 1995; 86: 1203-1209.
24. Theodoridis G, Laskaris G, de Jong CF, Hofte AJP and Verpoorte R. Determination of paclitaxel and related diterpenoids in plant extracts by high-performance liquid chromatography with UV detection in high-performance liquid chromatography - mass spectrometry. Journal of Chromatography A 1998; 802: 297-305.
25. US Food and Drug Administration. Treatment IND. FDA: Rockville, MD, 1992; T92-32.
26. Vaishampayan U, Parchment RE, Jasti BR and Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 1999; 54: 22-29.
27. Wang LZ, Ho PC, Lee HS, Vaddi HK, Chan YW and Yung CS. Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay. Journal of Pharmaceutical and Biomedical Analysis 2003; 31: 283-289.
28. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society 1971; 9: 2325-2327.
29. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, Kanamaru R, Kasai Y, Koizumi W, Sakata Y and Taguchi T. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002; 2: 90-95.